CoImmune Announces Positive Results from Phase I/II Clinical Trial of Allogeneic CAR-CIK Cells in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia

CoImmune, Inc. announced that results from a Phase I/II clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company’s chimeric antigen receptor modified cytokine induced killer cell platform, demonstrated sustained responses in pediatric and adult patients with B-cell acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic stem cell transplantation.